详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)

文献详情

资源类型：

作者：

机构： [1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN, [2]Jilin Cancer Hospital, Changchun/CN, [3]Guangdong Lung Cancer Institute, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou/ CN, [4]Beijing Cancer Hospital/institute, Beijing/CN, [5]The 307Th Hospital of Chinese People’s Liberation Army, Beijing/CN, [6]The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou/CN, [7]Hubei Cancer Hospital, Wuhan/CN, [8]Nanjing General Hospital of Nanjing Military Command, Nanjing/CN, [9]Fourth Hospital of Hebei Medical University, Shijiazhuang/CN, [10]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu/CN, [11]Peking University Third Hospital, Beijing/CN, [12]Chinese People’s Liberation Army General Hospital, Beijing/CN, [13]Fujian Cancer Hospital, Fuzhou/CN, [14]Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN, [15]Cancer Center, Sun Yat-Sen University, Guangzhou/CN, [16]Imed Asia, Astrazeneca, Shanghai/CN

出处：

DOI：

ISSN：

关键词： ctDNA gefitinib EGFR

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 [2]MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. [3]Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report [4]Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. [5]EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs [6]Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged >= 75 Years: Subgroup Analysis of LUX-Lung 7 [7]Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials [8]Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial [9]EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs [10]Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial